The study of hypoxia imaging using FAZA

The study of hypoxia imaging using FAZA(1-(5-[18 F]Fluoro-5-deoxy-alpha-D-arabinofuranosyl)-2-nitroimidazole)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200225

Enrollment

Registered

2020-12-04

Start date

2020-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor, ischemic disease

Interventions

Use of [F-18]FAZA(1-(5-[18 F]Fluoro-5-deoxy-a-D-arabinofuranosyl)-2-nitroimidazole)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Assured for (F-18) FDG PET/CT, greater than or equal to 20 year of age with written informed consent

Exclusion criteria

Exclusion criteria: BS greater than or equal to 200mg/dl, pregnancy or suspected , without infromed consent

Design outcomes

Primary

Measure	Time frame
Accuracy, false positve rate, and false negative rate of [F-18] FAZA PET/CT	—

Contacts

Public ContactJunichi Tsuchiya

Institute of Science Tokyo Hospital

tcymrad@tmd.ac.jp+81-3-5803-5311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026